Stress Management Toolkit for People Living With Dementia and Their Care Partners

October 2, 2023 updated by: Duke University

Development of a Dyadic Stress Management Toolkit for People Living With Dementia and Their Care Partners

The purpose of this study is to develop a prototype of a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home.

A human-centered design approach will be used to develop and user-test a prototype of a dyadic, tangible stress-management toolkit with and for PLWD and their care partners; and to explore the feasibility of collecting several stress-related outcomes. A total of 4 focus groups (n=3-4 dyads/group) will be convened to explore the experiences, perceptions, preferences, and recommendations of dementia-caring dyads regarding stress, stress management, and key components and features of a stress management toolkit. Eligible tools for the toolkit include low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. Ten dyads who were not involved in prototype development will then use the toolkit for 2 weeks. Feedback on usability, feasibility, and acceptability will be collected through questionnaires (end of weeks 1 and 2) and 3 focus groups (3-4 dyads/group at end of week 2). We will collect stress-related, participant-reported outcomes (e.g., neuropsychiatric symptoms of dementia, caregiver stress, dyadic relationship strain), and saliva biospecimens from participants with dementia and their care partners at baseline and end of week 2, to explore their utility as endpoints in a future toolkit intervention that uses a single-arm, pre-post study design. Results will yield valuable data to support development and preliminary testing of a stress management toolkit intervention in a future pilot study.

This study involves human subjects and is expected to yield no more than minimal risk. Tools eligible for the toolkit must have demonstrated high degrees of safety in prior research. Major risks for participation include the potential for negative emotional responses to focus group discussions and surveys pertaining to stress, excess time burden to participate in the study, and breach of confidentiality. It is not anticipated, but there is a potential for physical discomfort if tools are not used as directed, which is why the toolkits will include a user guide outlining safety information, which a research team member will review with each participant prior to use.

Study Overview

Status

Recruiting

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • North Carolina
      • Durham, North Carolina, United States, 27705
        • Recruiting
        • Caregiver and dementia community support organizations
        • Contact:
          • Melissa L Harris

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion criteria for participants with dementia are:

  • age 60 years and over with a diagnosis of dementia of any type
  • able to express self verbally
  • English speaking.

Exclusion criteria for participants with dementia is:

• has a hearing or visual impairment that limits their ability to participate in the screening process or to participate in a focus group.

Inclusion criteria for care partner participants are:

  • age 21 years and older
  • identify as a primary care partner of someone with dementia
  • English speaking

Exclusion criteria for care partner participants is:

• has a hearing or visual impairment that limits their ability to participate in the screening process or to participate in a focus group.

Dyadic eligibility criteria include:

  • both the PLWD and care partner reside in the same household or personal residence in the community
  • dyad has lived together for at least 1 month
  • dyad has telephone or internet access
  • Dyads will be excluded if they reside in assisted living or other long-term care setting.

Dyads participating in user-testing phase will also be excluded if either member:

  • currently receives cytokine-based therapy
  • currently receives radiation therapy to the salivary glands or thyroid
  • are diagnosed with Cushing or Addison's disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Stress Management Toolkit Prototype Development
3-4 qualitative focus groups (n=3-4 dyads/group) will be held to explore experiences, perceptions, preferences, and recommendations of dementia-caring dyads regarding stress, stress management, and key components and features of a stress management toolkit. Eligible tools for the toolkit include low burden, high safety tools (e.g., weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy, bright light therapy devices, massage and acupressure tools).
Experimental: Stress Management Toolkit Prototype User Testing
10 dyads will use the toolkit for 2 weeks in their own homes. Feedback on usability, feasibility, and acceptability will be collected through questionnaires and focus groups. Stress-related, participant-reported outcomes (e.g., neuropsychiatric symptoms of dementia, caregiver stress, dyadic relationship strain), and salivary cortisol biospecimens will be collected at baseline and end of week 2, to explore their utility as endpoints in a future pilot study to examine efficacy.
The toolkit will be a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home. Potential tools for the toolkit includes low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. The tookit will also include user-safety guidelines and directions on how to use each tool. Tools will be included for participants with dementia and care partners.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of toolkit use
Time Frame: End of week 1 of user-testing period
Number of days toolkit was used over the last week (range 0-7) will be assessed among participants enrolled in user-testing arm.
End of week 1 of user-testing period
Frequency of toolkit use
Time Frame: End of week 2 of user-testing period
Number of days toolkit was used over the last week (range 0-7) will be assessed among participants enrolled in user-testing arm.
End of week 2 of user-testing period
Enrollment rate
Time Frame: Through study completion, an average of 1 year
Percentage of participant dyads enrolled/dyads screened in user-testing arm.
Through study completion, an average of 1 year
Withdrawal rate
Time Frame: Through study completion, an average of 1 year
Percentage of dyads that withdraw/dyads enrolled in user-testing arm.
Through study completion, an average of 1 year
Frequency of adverse events and injuries
Time Frame: Through study completion, an average of 1 year
Number of adverse events and injuries reported in user-testing arm.
Through study completion, an average of 1 year
Participant satisfaction with toolkit, as assessed using a toolkit satisfaction scale
Time Frame: Within 1 week after user-testing period
Investigator developed multi-item satisfaction scale will include Likert-scaled items pertaining to satisfaction with design and delivery of the toolkit among participants in the user-testing arm; item ranges 1=not satisfied at all to 5 very satisfied). Scores will be averaged to yield and overall satisfaction score with higher scores indicating a greater degree of satisfaction.
Within 1 week after user-testing period
Participant perceived benefit with toolkit, as assessed using a toolkit benefit scale
Time Frame: Within 1 week after user-testing period
Investigator developed multi-item benefit scale will include Likert-scaled items pertaining to perceived benefit from the toolkit among participants in the user-testing arm; item ranges 1=not beneficial at all to 5 very beneficial). Scores will be averaged to yield and overall benefit score with higher scores indicating a greater degree of benefit.
Within 1 week after user-testing period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of participant completion of neuropsychiatric symptoms of dementia outcome measure, as assessed using the Neuropsychiatric Inventory-Questionnaire
Time Frame: Baseline, pre user-testing period
Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at baseline/total number of participants enrolled in user-testing arm). NPI assesses severity (1=mild, 2=moderate, 3=severe) and caregiver distress (range 0=not distressing at all to 5 extreme or very severe) of 12 domains of neuropsychiatric symptoms of dementia. Higher scores indicate more severe or distressing symptoms.
Baseline, pre user-testing period
Percentage of participant completion of neuropsychiatric symptoms of dementia outcome measure, as assessed using the Neuropsychiatric Inventory-Questionnaire
Time Frame: Within 1 week after user-testing period
Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at post user-testing/total number of participants enrolled in user-testing arm). NPI assesses severity (1=mild, 2=moderate, 3=severe) and caregiver distress (range 0=not distressing at all to 5 extreme or very severe) of 12 domains of neuropsychiatric symptoms of dementia. Higher scores indicate more severe or distressing symptoms.
Within 1 week after user-testing period
Percentage of participant completion of caregiver stress outcome measure, as assessed using the Perceived Stress Scale
Time Frame: Baseline, pre user-testing period
Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at baseline/total number of participants enrolled in user-testing arm). The Perceived Stress Scale is a 10-item measure that assesses recent stress-related thoughts and feelings on 5-point scale with higher scores indicating higher levels of stress.
Baseline, pre user-testing period
Percentage of participant completion of caregiver stress outcome measure, as assessed using the Perceived Stress Scale
Time Frame: Within 1 week after user-testing period
Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at post user-testing/total number of participants enrolled in user-testing arm). The Perceived Stress Scale is a 10-item measure that assesses recent stress-related thoughts and feelings on 5-point scale with higher scores indicating higher levels of stress.
Within 1 week after user-testing period
Percentage of participant completion of dyadic relationship strain outcome measure, as assessed using the Dyadic Relationship Scale
Time Frame: Baseline, pre user-testing period
Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at baseline/total number of participants enrolled in user-testing arm). The Dyadic Relationship Scale includes a care recipient 10-item version and care partner specific 11-item version. Both scales measure dyadic strain and positive dyadic interaction. Total scores range from 0-30 for the care recipient version, and 0-33 for care partner specific, with higher scores indicative of higher levels of dyadic strain.
Baseline, pre user-testing period
Percentage of participant completion of dyadic relationship strain outcome measure, as assessed using the Dyadic Relationship Scale
Time Frame: Within 1 week after user-testing period
Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at post user-testing/total number of participants enrolled in user-testing arm). The Dyadic Relationship Scale includes a care recipient 10-item version and care partner specific 11-item version. Both scales measure dyadic strain and positive dyadic interaction. Total scores range from 0-30 for the care recipient version, and 0-33 for care partner specific, with higher scores indicative of higher levels of dyadic strain.
Within 1 week after user-testing period
Percentage of participant completion of physiologic stress outcome measure, as assessed through salivary cortisol biospecimens
Time Frame: Baseline, pre user-testing period

Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Total number of biospecimen samples collected among participants at baseline/total number of participants enrolled in user-testing arm*5).

Salivary cortisol biospecimens will be collected using salivary sample kits sent to participants' homes by mail. Participants with dementia and care partners will each be asked to collect 5 samples at baseline and will collect samples themselves in their own homes with guidance and support from research team. Samples will be mailed back to research team using preaddressed, prestamped envelopes.

Baseline, pre user-testing period
Percentage of participant completion of physiologic stress outcome measure, as assessed through salivary cortisol biospecimens
Time Frame: Within 1 week after user-testing period

Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Total number of biospecimen samples collected among participants at post user-testing/total number of participants enrolled in user-testing arm*5).

Salivary cortisol biospecimens will be collected using salivary sample kits sent to participants' homes by mail. Participants with dementia and care partners will each be asked to collect 5 samples at post user-testing and will collect samples themselves in their own homes with guidance and support from research team. Samples will be mailed back to research team using preaddressed, prestamped envelopes.

Within 1 week after user-testing period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Melissa L Harris, PhD, Duke University School of Nursing
  • Principal Investigator: Susan N Hastings, MD, Duke University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 20, 2022

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

July 30, 2024

Study Registration Dates

First Submitted

June 27, 2022

First Submitted That Met QC Criteria

July 14, 2022

First Posted (Actual)

July 20, 2022

Study Record Updates

Last Update Posted (Actual)

October 3, 2023

Last Update Submitted That Met QC Criteria

October 2, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress

Clinical Trials on Stress Management Toolkit

3
Subscribe